Thrombotic thrombocytopenic purpura is associated with acquired or congenital deficiency of a plasma von Willebrand factor-cleaving protease (VWFCP). Based on partial amino acid sequence, VWFCP was identified recently as a new member of the ADAMTS family of metalloproteases and designated ADAMTS13. The 4.6-kilobase pair cDNA sequence for VWFCP has now been determined. By Northern blotting, full-length VWFCP mRNA was detected only in liver. VWFCP consists of 1427 amino acid residues and has a signal peptide, a short propeptide terminating in the sequence RQRR, a reprolysin-like metalloprotease domain, a disintegrinlike domain, a thrombospondin-1 repeat, a Cys-rich domain, an ADAMTS spacer, seven additional thrombospondin-1 repeats, and two CUB domains. VWFCP apparently is made as a zymogen that requires proteolytic activation, possibly by furin intracellularly. Sites for Zn 2؉ 
Thrombotic thrombocytopenic purpura (TTP)
1 is a syndrome characterized by microangiopathic hemolytic anemia and thrombocytopenia, and it may be accompanied by neurological dysfunction, renal failure, and fever (1, 2) . TTP often strikes young adults, mainly females, suggesting an autoimmune etiology. If untreated, the mortality may exceed 90% (2), but plasma exchange therapy has reduced the mortality to less than 20% (3) .
The basis for the efficacy of plasma exchange remains unknown, although a plausible model has been suggested in which the proteolysis of von Willebrand factor (VWF) plays a central role. In 1982, patients with chronic relapsing TTP were reported to have "unusually large" VWF multimers (UL-VWF) because of the absence of a VWF depolymerase activity. Binding of UL-VWF to platelets could promote microvascular thrombosis, platelet consumption, and hemolysis. Therapeutic infusion of plasma was proposed to replace the missing depolymerase activity or other factors and thereby limit VWF-dependent platelet thrombosis (4) . Later discoveries have strengthened the relationship between VWF proteolysis and TTP. A plasma metalloprotease was identified that requires both calcium and zinc ions and cleaves the Tyr 1605 -Met 1606 bond 2 in the central A2 domain of the VWF subunit (5, 6) . Cleavage was stimulated by shear forces like those occurring at sites of arterial thrombosis or by low concentrations of urea or guanidine. Furthermore, most adult patients with TTP were found to have congenital deficiency or an acquired autoantibody inhibitor of this VWF-cleaving protease (VWFCP) (7) (8) (9) . These findings are consistent with the UL-VWF model of TTP pathogenesis. Alternatively, it is possible that failure to cleave another unknown substrate contributes to the pathogenesis of TTP.
VWFCP was recently purified from human plasma sources, and an N-terminal amino acid sequence was obtained (10, 11) . This information showed it to be a member of the ADAMTS family of metalloproteases, named for the characteristic combination of a disintegrin-like and metalloprotease (reprolysintype), with thrombospondin type 1 motif (12) (13) (14) . Furthermore, the VWFCP gene was identified with the partially characterized C9ORF8 gene on chromosome 9 (11) . Completion of the cDNA sequence now shows the VWFCP gene to be much more extensive than predicted. The deduced protein sequence indicates that VWFCP is similar in structure to other ADAMTS proteases but with unique features that suggest distinct modes of ligand binding. Alternatively spliced transcripts were characterized that change the domain architecture and may have functional consequences for the interaction of VWFCP with extracellular matrix, cell surfaces, substrates, and other proteins.
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The . DNA fragments between these sequences were generated by PCR with Marathon RACE-ready human liver cDNA and Advantage TM 2 PCR kit (CLONTECH, Palo Alto, CA) using primers 5Ј-CCT CAC CCG CCC AGA CAT CAC CTT-3Ј (nt 2109 -2132) and 5Ј-GGG CTG GCC AGA CAC GGA ACA AAT-3Ј (nt 4405-4428 complement). The sequence between nt 830 and 2153 was amplified with primers 5Ј-GCT GCG GCC CCA GCG GAC ACG T-3Ј (nt 830 -851) and 5Ј-GGC TTA GGC TGG AAG TAG GTG-3Ј (nt 2133-2153 complement) using human liver PCR-ready cDNA (Ambion, Austin, TX) and Advantage TM -GC 2 PCR kit (CLONTECH). Additional partial human cDNAs for VWFCP were isolated from HepG2, brain, and prostate libraries by screening subdivided library pools by PCR using the primers 5Ј-GTG GGG TGC TGC TGC GGT AT-3Ј (nt 3947-3966) and 5Ј-ACC CCC TAG-CCT TTT GGA CAT TGG A-3Ј (nt 4505-4529 complement). PCR products were cloned into plasmid pCR2.1 (Invitrogen, Carlsbad, CA) and sequenced.
Sequence Analysis-Consensus cDNA sequences for VWFCP were compared with human chromosome 9 sequences, draft mouse chromosome 2 sequences, and homologous protein sequences with the Lasergene suite of programs (DNASTAR, Madison, WI). Human and mouse VWFCP genomic DNA sequences were compared with the program VISTA (17, 18) to identify conserved exons. Human VWFCP protein sequence was scanned for structural domains using reverse positionspecific BLAST (19) and the Conserved Domain Data base at NCBI (www.ncbi.nlm.nih.gov), ProDom (20) , and Pfam (21) . The proposed signal peptide was identified with the program SignalP v1.1 (22) .
Northern Blotting-The cDNA insert of expressed sequence tag clone 1870768 (GenBank TM AI245927), containing VWFCP nt 1-932, was isolated by digestion with NotI and EcoRI, labeled with [␣-32 P]dCTP (3000 Ci/mmol, Amersham Pharmacia Biotech) using a random primer DNA labeling system (18187-13; Life Technologies, Inc.) and purified on a Centri-SEP spin column (Princeton Separations, Adelphia, NJ). Human multiple Northern (MTN TM ) blot I (7780 -1) and blot II (7759 -1) were hybridized at 68°C with heat-denatured probe (2.0 ϫ 10 5 cpm/ml) for one h after 30 min prehybridization with ExpressHyb TM solution (CLONTECH). Membranes were washed sequentially with 2ϫ SSC, 0.1% SDS at 25°C and 0.1ϫ SSC, 0.5% SDS at 50°C for 30 min and exposed to Kodak X-OMAT film at Ϫ70°C with one screen for 3 days. The membranes were stripped and rehybridized with [␣-32 P]dCTP-labeled human ␤-actin cDNA (23) and exposed for 1 h.
RESULTS
Characterization of cDNA Clones-The amino acid sequence of purified plasma VWFCP enabled the identification of the VW-FCP gene with the hypothetical C9ORF8 gene on human chromosome 9. Sequence comparisons showed that VWFCP belongs to the ADAMTS family of metalloproteases (10, 11) . The predicted 2.2-kb cDNA sequence of C9ORF8 contains several insertions and frameshifts and lacks all or parts of the signature propeptide, protease, and spacer domains of ADAMTS proteases (13, 14) . Analysis of human chromosome 9 for predicted transcripts (15, 16) suggested that the C9ORF8 locus was part of a much larger transcription unit that contained at least 28 exons, spanned at least 37 kb, and included the adjacent hypothetical DKFZp424C2322 locus (24) . Comparison of this human chromosome 9 segment with mouse genome sequences allowed the assembly of a mouse chromosome 2 sequence for this locus from clones rp23-163 h21 (GenBank TM AC090008) and rp23-151n4 (GenBank TM AC091762). Alignment of the mouse and human sequences (17, 18) identified 29 conserved exons and resolved several ambiguities in the predicted splicing patterns. With this framework, cDNA clones were isolated by screening cDNA libraries and by PCR of human liver cDNA. The assembled full-length cDNA sequence (GenBank TM AY055376) includes 4597 nt plus a poly(A) tail, with a 4284-nt open reading frame (nt 109 -4392) preceded by in-frame termination codons.
Protein Structure and Domain Organization-The deduced protein sequence of human VWFCP contains 1427 amino acid residues (see Fig. 1 and Fig. 2) . The predicted N-terminal signal peptide precedes a 41-residue propeptide that ends in the sequence RQRR, which is followed by the experimentally determined N-terminal protein sequence of plasma VWFCP (10, 11) . Similar basic propeptide cleavage sites occur in other ADAMTS proteases and often are cleaved intracellularly by furin during biosynthesis (13) . The next domains comprise the defining motifs of the ADAMTS family, a reprolysin-like metalloprotease domain, a disintegrin-like domain, a thrombospondin-1 repeat (TSP1), and characteristic Cys-rich and spacer domains (12) (13) (14) . The Cys-rich domain of VWFCP has an RGDS sequence that could bind to integrins on platelets or other cell types. An RGD sequence is present in the Cys-rich domain of ADAMTS-2 (procollagen I N-proteinase) (25) but not in the 10 other known mammalian ADAMTS proteases.
In VWFCP, the spacer domain is followed by seven more TSP1 repeats. ADAMTS proteases often have a variable number of TSP1 repeats in locations similar to those of VWFCP. For example, ADAMTS9 (long form) has 12 TSP1 repeats after its spacer domain (26, 27 von Willebrand Factor-cleaving Proteasewhich is encoded by two exons, each of these additional TSP1 repeats in VWFCP is encoded by one exon (Fig. 2) . TSP repeat 4 is unusual for the absence of two conserved Cys residues that are present, however, in the homologous TSP1 repeat 4 of mouse VWFCP (not shown). The TSP1 repeats of VWFCP are followed by two CUB domains (28), which were first identified in complement components C1r and C1s. VWFCP is the only known ADAMTS protease with CUB domains, and this distinctive domain structure is reflected in the evolutionary relationships among ADAMTS proteases. Comparison of the protease, TSP1, and Cys-rich and spacer domain sequences shows that VWFCP is the most divergent member of the family (Fig. 2) . The VWFCP protease domain has the expected hallmarks of the reprolysin (29) or adamalysin (30) family of metalloproteases. These include (Fig. 1) 75 and has a calculated polypeptide mass of 145 kDa, compared with the apparent mass of ϳ190 kDa for VWFCP purified from human plasma (11) . The difference may be because of glycosylation. VWFCP has 10 potential N-glycosylation sites (Asn-Xaa-Thr/ Ser) (Fig. 1) , and the TSP1 repeats have additional sites for specific, unusual oligosaccharides (Fig. 3) . TSP1 repeat 1 contains the sequence WXXW, which often is modified in TSP1 repeats by attachment of an ␣-mannosyl group to the C-2 atom of the first Trp (32) . Seven of the eight TSP1 repeats also contain the conserved sequence CSX(S/T)CG, in which the hy- 
FIG. 4. VWFCP mRNA in human tissues. Northern blots containing samples of poly(A)
ϩ RNA from the indicated human tissues were hybridized to a probe corresponding to the 5Ј 932 nt of the human VWFCP cDNA sequence (upper panels) or human ␤-actin (lower panels) as described under "Experimental Procedures." The size of RNA markers is indicated at the left.
von Willebrand Factor-cleaving Proteasedroxyamino acid at position 4 usually is modified by the disaccharide Glc-Fuc-O-Ser/Thr (32) .
Expression of VWFCP and Alternative Splicing-Northern blotting of human poly(A)
ϩ mRNA identified a 4.7-kb mRNA in liver and a 2.4-kb mRNA in placenta and skeletal muscle (Fig.  4) . Therefore, liver may be mainly responsible for the synthesis of full-length VWFCP. By the more sensitive method of reverse transcriptase-PCR using primers specific for the first CUB domain and 3Ј noncoding sequence, all tissues examined show PCR products characteristic of the VWFCP (not shown), suggesting that VWFCP or variant forms of it are expressed at low levels in all tissues. Accordingly, partial cDNAs for VWFCP were isolated from brain and prostate in addition to liver.
Comparison of the cDNA sequences with genomic sequences identified seven alternatively spliced transcripts, three of which were observed in liver. The use of alternate donor or acceptor sites gave rise to transcripts with deletions of nt 933-937 (liver), 2197-2212 (liver), 3997-4185 (liver), 4004 -4185 (brain), 3510 -3676 (prostate), or 2198 -2528 (prostate). In another brain transcript, the use of an alternate acceptor site results in the insertion of 235 nt at the 5Ј end of exon 8. These insertions and deletions cause frameshifts and truncation after the metalloprotease domain, the spacer domain, or the first CUB domain or cause an in-frame deletion of 56 amino acids between the eighth TSP1 domain and the first CUB domain.
DISCUSSION
The domain structure of VWFCP indicates that it belongs to the ADAMTS family of metalloproteases, and VWFCP has been designated ADAMTS13 (HUGO Gene Nomenclature Committee, www.gene.ucl.ac.uk/nomenclature). The properties of other members of this family may be relevant to understanding the biological function of VWFCP. ADAMTS1 is required for normal development of the genitourinary system; deficiency causes obstructive ureteropelvic fibrosis and defects in renal and adrenal morphology (33) . Procollagen I N-proteinase (ADAMTS2) releases N-terminal propeptides from procollagens I and II, permitting the extracellular assembly of collagen fibrils. Deficiency of procollagen I N-proteinase causes human Ehlers-Danlos syndrome type VIIC, which is associated with fragile skin and hyperextensible joints (25) . ADAMTS3 also has procollagen II Nproteinase activity (34) . Aggrecanase-1 (ADAMTS4) (35) (36) (37) , aggrecanase-2 (ADAMTS5) (38) , and ADAMTS1 (37, 39) cleave proteoglycans of cartilage (aggrecan), brain (brevican), or artery wall (versican V1) in vitro at peptide bonds that also are cleaved in vivo. VWF may be thought of as a mobile connective tissue component that is incorporated at sites of vascular injury, where it mediates platelet adhesion and is cleaved by VWFCP (AD-AMTS13). From this perspective, the known activities of AD-AMTS proteases involve the processing of adhesive glycoproteins in extracellular matrix.
Other ADAMTS proteases have propeptides of ϳ160 to ϳ230 amino acid residues that contain two or three Cys residues. In many metalloproteases including the ADAMTS family, a Cys residue in the propeptide is proposed to maintain latency of the protease activity by coordinating the catalytic Zn 2ϩ residue (40, 41) . However, VWFCP has a propeptide of only 41 residues with one Cys that is not in a typical "cysteine switch" environment (Fig. 1) . Whether a cysteine switch mechanism operates in human VWFCP is not known, and residue Cys 35 is not conserved in the propeptide of mouse VWFCP, being replaced by Leu (not shown). The VWFCP propeptide ends with the sequence RQRR, which suggests that furin or a related processing protease cleaves it during synthesis. Other ADAMTS propeptides are cleaved at similar sites by furin, either in the Golgi or at the cell surface (42) (43) (44) . Therefore, VWFCP may be secreted as an active protease. Alternatively, extracellular cleavage and activation of proVWFCP could be regulated, providing an additional level of biological control.
Structural domains that follow the disintegrin-like domain can determine the tissue localization of certain ADAMTS proteases and may function similarly in VWFCP. Recombinant ADAMTS1 binds the extracellular matrix of cultured cells. Matrix binding can be mediated by the spacer domain or by several TSP1 repeats and is reversed by heparin, suggesting that ADAMTS1 binds glycosaminoglycans (45) . Recombinant ADAMTS12 also binds to extracellular matrix (44) . In another context, the TSP1 repeats of platelet thrombospondin appear to bind several glycoproteins and proteoglycans on cell surfaces and in extracellular matrix (46) , as well as fibrinogen or fibrin (47) . TSP1 repeats were discovered recently to bear two unusual post-translational modifications, an ␣-mannosyl group on the C-2 position of Trp and the disaccharide Glc-Fuc-O-Ser/ Thr in the motif CSX(S/T)CG (32) . These modifications are located within segments of TSP1 repeats that are implicated in ligand binding (reviewed in Ref. 46) . Consensus sites for Cmannosylation and O-fucosylation occur in the TSP1 repeats of VWFCP (Fig. 3) and may contribute to normal biological function.
The CUB domains of VWFCP are not found in other known ADAMTS proteases but are characteristic of a distantly related metalloprotease subfamily that includes procollagen C-proteinase (synonyms, mTolloid and BMP-1), mammalian tolloid-like proteins 1 and 2, Xenopus hatching enzyme UVS.2, and sea urchin BP10/SpAN (reviewed in Ref. 48 ). All of these proteins contain an astacin-like metalloprotease domain followed by one or more epidermal growth factor domains and up to five CUB domains. The CUB domains of procollagen C-proteinase bind to procollagen, thereby contributing to substrate recognition (48) . In addition, normal procollagen C-processing requires a cofactor protein, procollagen C-proteinase enhancer, that has two CUB domains and also binds procollagen (49) . These examples suggest the CUB domains of VWFCP may interact with physiological ligands.
Alternative splicing is a common feature of ADAMTS gene expression (12) (13) (14) , and seven variant transcripts for VWFCP were identified in this study that truncate the predicted protein sequence after the metalloprotease domain, the spacer domain, or the first CUB domain. Alternative splicing may account for the shorter 2.4-kb transcripts found in placenta and skeletal muscle, as well (Fig. 4) . Whether these various transcripts can give rise to functional protein is not known. However, alternative splicing may explain some of the size heterogeneity of plasma VWFCP, which may consist of 150-, 140-, 130-, and 110-kDa species that share a common N-terminal sequence (10) . Furthermore, alternative splicing could produce several protein products with distinct abilities to interact with cofactors, extracellular matrix, platelets, and VWF.
The association of VWFCP deficiency with TTP is convincing (7-9), but the mechanism of deficiency is apparent for only the one-half of adult patients with anti-VWFCP antibodies and the rare patients with congenital VWFCP deficiency. VWFCP cleaves VWF at a unique Tyr-Met bond (5, 6) , and deficiency of VWFCP leads to the accumulation of UL-VWF multimers. However, the spectrum of physiological substrates for VWFCP may be broader than VWF alone, and the role of UL-VWF in the pathogenesis of TTP is not fully understood. The characterization of the VWFCP (ADAMTS13) cDNA will facilitate the investigation of these important biochemical and medical questions and may lead to the development of more specific treatments for TTP.
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